SUPN News and Press, Supernus Pharmaceuticals Inc. From 09/14/20

ROCKVILLE, Md., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it has submitted a New Drug Applicat...

ROCKVILLE, Md., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will presen...

ROCKVILLE, Md., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will presen...

Supernus Pharmaceuticals, Inc. (SUPN) Q2 2020 Earnings Conference Call August 19, 2020 09:00 AM ET Company Participants Peter Vozzo - IR, Westwicke Jack Khattar - President and CEO Greg Patrick - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sa...

Image source: The Motley Fool. Supernus Pharmaceuticals Inc   (NASDAQ: SUPN) Q2 2020 Earnings Call Aug 19, 2020 , 9:00 a.m. ET Operator Continue reading

For Q2 , Supernus Pharmaceuticals ( SUPN -4.6% ) reported revenue of $126.73M (+21.0% Y/Y)  missed consensus by $5.27M . More news on: Supernus Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

Total revenue of $126.7 million, including net product sales of $89.7 million for Trokendi XR®, $23.7 million for Oxtellar XR®, and $10.6 million for the acquired Parkinson’s disease (PD) products Operating earnings of $45.5 million Completed acquisition of CNS portfolio...

Supernus Pharmaceuticals (NASDAQ: SUPN ) : Q2 GAAP EPS of $0.65 beats by $0.16 . More news on: Supernus Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

This article series shows every month a dashboard with aggregate industry metrics in healthcare (popular ETFs in this sector: XLV , IYH , IBB , XBI , VHT , XPH ). Shortcut If you are used to this dashboard series or if you are short on time, you can skip the first paragraphs and go...

Second quarter total revenue is estimated to be $126.7 million, a 21% increase over 2019 Net product sales of Trokendi XR® and Oxtellar XR® are estimated to be $113.4 million, an 11% increase over 2019 Completed acquisition of CNS portfolio of US WorldMeds on June 9, 2020 ...